• Explore /
  • Poster
  • / Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.

Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study.

Abstract Poster

Authors

null

Igor Puzanov

Vanderbilt University Medical Center, Nashville, TN

Igor Puzanov , Jeffrey Alan Sosman , Armando Santoro , Robert E. Martell , Grace K. Dy , Laura Williams Goff , Wen Wee Ma , Gerald J. Fetterly , Shaunita A. Michael , Julie Ann Means-Powell , Feng Chai , Maria Lamar , Gary M. Strauss , Paolo A. Zucali , Wendy M. Chiang , Jamie Jarboe , Brian E. Schwartz , Alex A. Adjei

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Nonprostate) Cancer

Track

Genitourinary Cancer

Sub Track

Kidney Cancer

Clinical Trial Registration Number

NCT00827177

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4545)

DOI

10.1200/jco.2012.30.15_suppl.4545

Abstract #

4545

Poster Bd #

24

Abstract Disclosures

Similar Posters

First Author: Robert E. Martell

First Author: Markus H. Moehler

First Author: Aaron C. Tan

First Author: Funda Meric-Bernstam